126
|
Misset JL, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenburg L, Machover D, Ribaud P, De Vassal F, Horosezewicz JS. [Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon]. Biomed Pharmacother 1982; 36:55-9. [PMID: 6181822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Eighteen patients with malignant gammapathies (16 with myeloma and 2 with Waldenström's disease) for a short time because in a phase II-I trial were treated with human (IF beta) given i. v. 6 X 10(6) units weekly (7 patients) or 3 X 10(6) units twice weekly (11 patients) during at least 3 months if tolerated. Treatment was discontinued because of side-effects in three patients. Reduction of the M component of at least 25% from the initial value was obtained in 3 patients. In one case, was also observed in disappearance of the urinary Bence-Jones protein, in 4 cases a significant reduction of bone marrow infiltration by plasma cells and, in 5 cases, major alleviation or disappearance of bone pain. Length of treatment seems an important factor for activity. Immune monitoring with currently available tests, mainly NK cell activity, yielded no correlation with therapeutic effect in these patients. This very preliminary study demonstrates the effect of fibroblastic interferon in myeloma, but further studies are mandatory to determine the population of patients likely to benefit from treatment, the best modalities, possible special indication, dose schedule and duration of treatment. Interferon, however, already appears in this population of patients as giving results similar to those of single agent chemotherapy. As it is not myelosuppressive, it could be indicated in that frequent situation of advanced myeloma with bone marrow failure contra-indicating combination chemotherapy.
Collapse
|
127
|
Misset JL, De Vassal F, Delgado M, Ribaud P, Musset M, Dorval T, Machover D, Jasmin C, Hayat M, Schwarzenberg L, Mathe G. An intensive care chemo- or chemoimmunotherapy regimen for patients with intermediate and poor-prognosis acute lymphatic leukemia and leukemic lymphoblastic lymphosarcoma: preliminary results with 14-month median follow-up. Recent Results Cancer Res 1982; 80:29-35. [PMID: 6949235 DOI: 10.1007/978-3-642-81685-7_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
128
|
Misset JL, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenberg L, Machover D, Ribaud P, De Vassal F. Treatment of lymphoid neoplasias with interferon. II. Human leucocyte alpha-interferon in chronic lymphatic leukemia (CLL). PHase I-II trial. Anticancer Res 1982; 2:67-9. [PMID: 6180676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Nine patients with chronic lymphoid leukemia (CLL) were treated with subcutaneous human (leukocyte) interferon a (IF a). In the first part of the study, 7 patients received intermittent 10 day courses, with free intervals of 10 to 15 days and with dose escalation in the same patient from cycle to cycle from 1.5 to 6 X 10(6) units daily, if tolerated. As we observed a decrease of peripheral lymphocytosis with low doses, and as high doses gave more side-effect in the second part of the study, 4 patients (including two who has previously received intermittent courses) were treated for three months or more at a dose of 1.5 X 10 units daily. Tumor mass reduction was seen in only three patients. However, a significant decrease in peripheral lymphocytosis was seen in 7 patients who were sustained in the continuous treatment group; with relapse at treatment discontinuation in one patient and despite continuation in another. Immune monitoring with currently available T, B, NK and macrophage tests, showed a good correlation between NK cell activity and clinical response, in this group of patients. Further studies are warranted to determine the best modalities of treatment, the population of patients likely to benefit from such treatment, the possible special respective indications of IF, and also the other treatments of CLL. One can already consider as a reasonable indication CLL presentations with myeloid insufficiency as IF is not myelotoxic, contrary to chemotherapy.
Collapse
|
129
|
Misset JL, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenberg L, Machover D, Ribaud P, De Vassal F, Horoszewicz JS. Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial. Anticancer Res 1982; 2:63-6. [PMID: 6180675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
18 patients with malignant gammapathies (16 with myeloma and 2 with Waldenström's disease) were treated with human fibroblastic Interferon (beta IF). This was administered i.v. 6 X 10(6) units weekly (7 patients) or 3 X 10(6) units twice weekly (11 patients). during at least 3 months if tolerated. Treatment was discontinued because of side effects in three patients. Reduction of the M component, by at least 25% from the initial value, was obtained in 3 patients. In one case the disappearance of a urinary Bence Jones protein was observed. In 4 cases, there was a significant reduction of bone marrow infiltration by plasma cells. In 5 cases, major alleviation or disappearance of bone pain was observed. Duration of treatment seemed to be an important factor for activity. Immune monitoring with currently available tests, mainly natural cytoxicity, yielded no correlation with therapeutic effect in these patients. This preliminary study demonstrates the effect of fibroblastic Interferon in myeloma. However, further studies are necessary to determine the population of patients most likely to benefit from treatment, the best modalities, possible special indications, dose schedules and duration of treatment. As it is not myelosuppressive it could be indicated in the frequent situation of advanced myeloma with bone marrow failure, contra-indicating combination chemotherapy.
Collapse
|
130
|
Tubiana M, Hayat M, Henry-Amar M, Breur K, van der Werf Messing B, Burgers M. Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. Eur J Cancer 1981; 17:355-63. [PMID: 7021162 DOI: 10.1016/0014-2964(81)90128-6] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
131
|
Pene F, Henry-Amar M, Le Bourgeois JP, Hayat M, Gerard-Marchant R, Laugier A, Mathe G, Tubiana M. A study of relapse and course of 153 cases of Hodgkin's disease (clinical stages I and II) treated at the Institute Gustave-Roussy from 1963 to 1970 with radiotherapy alone or with adjuvant monochemotherapy. Cancer 1980; 46:2131-41. [PMID: 7000332 DOI: 10.1002/1097-0142(19801115)46:10<2131::aid-cncr2820461004>3.0.co;2-q] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
132
|
Mori KJ, Jasmin C, Hayat M, MacDonald JS, Mathé G. In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea. Cancer Res 1980; 40:4282-6. [PMID: 6451285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
133
|
Hayat M, Brulé G, Cappelaere P, Cattan A, Chauvergne J, Clavel B, Guerrin J, Misset JL, Pommatau E, Ribaud P, Muggia FM, Rozencweig M, Mathé G. Cisplatinumdiamminodichloride (CPDD) in chemotherapy of cancers: a phase II therapeutic trial. Recent Results Cancer Res 1980; 74:139-45. [PMID: 7192425 DOI: 10.1007/978-3-642-81488-4_18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
We have conducted a phase II trial of cisplatinumdiamminodichloride (CPDD) which not only demonstrated its remarkable activity in embryonic carcinoma of the testes, but also in ovarian carcinoma, in melanoma, and in epidermoid carcinoma, especially of the head and of the uterus cervix. Its toxicity, manifested mainly in the digestive and renal tracts, confines its administration to hospitalized patients only. This compound is now indicated in combination therapy for the above-mentioned tumors.
Collapse
|
134
|
Mathé G, Gil MA, Delgado M, Bayssas M, Gouveia J, Ribaud P, Machover D, Misset JL, de Vassal F, Schwarzenberg L, Jasmin C, Hayat M. Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma. Recent Results Cancer Res 1980; 74:217-22. [PMID: 6893752 DOI: 10.1007/978-3-642-81488-4_27] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
135
|
Dantchev D, Slioussartchouk V, Paintrand M, Bourut C, Hayat M, Mathé G. Ultrastructural study of the cardiotoxicity and light-microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent Results Cancer Res 1980; 74:223-49. [PMID: 7444141 DOI: 10.1007/978-3-642-81488-4_28] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Golden hamsters were administered seven anthracyclines: adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (eADM), rubidazone (RBZ), aclacinomycin (ACM), and N-trifluoroacetyladriamycin-14-valerate (AD-32), three times a week during 4 weeks, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. We examined their myocardia by electron microscopy (EM) and their skin by light microscopy (LM), and report here the findings of these two examinations. The mortality was very high for the groups of hamsters treated with ADM, DTR, DRB, eADM, and RBZ (all treated hamsters died before the end of the fourth week) and very low for those treated with ACM and AD-32 (for each drug, only one of the 21 treated animals died after 4 weeks of treatment). After the first week of treatment and chiefly after the second week, all treated hamsters, except those treated with ACM, showed very severe EM alterations of their myocardia. EM detected almost no early myocardial lesions in ACM-treated hamsters but, after 4 weeks of treatment, severe cardiac lesions also appeared which, like those after AD-32, were nonlethal and reversible. LM of the skin detected degenerative lesions with atrophy of all epidermic layers and a loss of the hair (alopecia) in all treated hamsters except those treated with ACM and AD-32; the skin in these two groups preserved its normal histologic structure. These observations agree with phase I-II clinical ACM studies in which the rate of ECG abnormalities was 4.5% and the rate of alopecia 0%, and with an early AD-32 clinical study conducted by Blum [3].
Collapse
|
136
|
Bayssas M, Gouveia J, de Vassal F, Misset JL, Schwarzenberg L, Ribaud P, Musset M, Jasmin C, Hayat M, Mathé G. Vindesine: a new vinca alkaloid. Recent Results Cancer Res 1980; 74:91-7. [PMID: 7003662 DOI: 10.1007/978-3-642-81488-4_13] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits the polymerization of tubulin. Its terminal half-life is 24 h and its plasma clearance is intermediate between those of vinblastine (VLB) and VCR. The maximal tolerated dose is 4-5 mg/m2/week, the dose-limiting toxicity being myelosuppression (nadir by days 7-8 and recovery by days 11-13). It has already been demonstrated as efficient in childhood acute lymphoid leukemia (ALL), non-Hodgkin's lymphoma, blastic crisis of chronic myeloid leukemia, and esophageal carcinoma. It has also shown activity in Hodgkin's disease, breast and germ cell carcinomas, and melanoma. Intolerance is mainly neurologic, with paresthesias, without motor impairment, or hematologic, with leukopenia, and sometimes alopecia, asthenia, and muscle pains. The results are better if the patients have not been treated previously; continuous infusion could be of interest and there appears to be no cross-resistance with its parent VCR, as documented in ALL.
Collapse
|
137
|
Hayat M, Bourut C, Chenu E, Montero JL, Imbach JL, MacDonald JS, Mathé G. Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. Cancer Chemother Pharmacol 1979; 3:217-21. [PMID: 161207 DOI: 10.1007/bf00254734] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
138
|
Bayssas M, Gouveia J, Ribaud P, Musset M, de Vassal F, Pico JL, de Luca L, Misset JL, Machover D, Belpomme D, Schwarzenberg L, Jasmin C, Hayat M, Mathé G. Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother Pharmacol 1979; 2:247-55. [PMID: 287569 DOI: 10.1007/bf00257189] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid luekemia (55%), and some responses were recorded in lymphosarcoma (40%). No effect has so far been seen in acute myeloid keukemia or in Hodgkin's disease. Malignant neoplasms of the immunoblastic type seem to be particularly sensitive to VDS. Continuous 48 h IV infusion can induce a remission where an IV push administration of the same dose has failed. One remarkable characteristic of VDS is the apparent absence of cross-resistance with VCR: in acute leukemic forms, 55% of patients who failed to obtain remission induction after three weekly injections of VCR (used in combination chemotherapy) achieved a complete or partial remission with VDS. The toxicity was mainly neurologic (paralytic ileus, constipation, paresthesias, loss of reflexes) and hematologic (leukopenia and thrombopenia), and was not more significant than with the other agents: four patients died of infection or hemorrhage.
Collapse
|
139
|
Mathé G, Schwarzenberg L, Vénuat AM, Rosenfeld C, Jasmin C, Ribaud P, Musset M, Misset JL, Machover D, de Vassal F, Hayat M. Splenectomy and karyotypic conversion in chronic myeloid leukaemia. Lancet 1979; 2:793-4. [PMID: 90884 DOI: 10.1016/s0140-6736(79)92139-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
140
|
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 1979; 32:1085-6. [PMID: 528374 DOI: 10.7164/antibiotics.32.1085] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
141
|
Mathé G, Gescher F, Bayssas M, Misset JL, Machover D, Gil MA, Delgado M, Ribaud P, Hayat M. Aclacinomycin A in acute leukaemias and lymphomas. Lancet 1979; 2:310-1. [PMID: 88646 DOI: 10.1016/s0140-6736(79)90330-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
142
|
Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bourut C, Mathé G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin. CANCER TREATMENT REPORTS 1979; 63:875-88. [PMID: 455329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Golden hamsters received Adriamycin (ADR), detorubicin (DTR), AD-32, or aclacinomycin (ACM) three times weekly at doses extrapolated from optimal doses in L1210 leukemia. Minimal early lesions of the myocardium were detected by electron microscopy in ACM-treated animals. These lesions were aggravated after several weeks of treatment but remained reversible. Lesions in AD-32-treated hamsters were slightly more marked than those seen in ACM-treated animals but were much less severe than those observed in ADR- or DTR-treated animals. Similarly, light microscopy revealed pathologic changes in the skin following ADR or DTR administration. These changes were not seen in animals receiving AD-32 or ACM.
Collapse
|
143
|
Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC. Adriamycin cardiotoxicity: a survey of 1273 patients. CANCER TREATMENT REPORTS 1979; 63:827-34. [PMID: 455324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Valuable information was collected on the medical history and clinical course of 1273 patients entered in clinical trials with Adriamycin (ADR) carried out in 12 European cancer centers. A coded patient form was used for the data collection carried out in each center by a qualified physician following a guideline which was discussed and accepted by all of the participants. The aim of the study was to define the incidence, characteristics, and possible co-factors of the cardiomyopathy (CMP) in patients treated with combination chemotherapy regimens including ADR. The mean total dose of ADR was 268 mg/m2 (range, 15--1251 mg/m2), and 5.1% of the patients received a total dose of greater than 550 mg/m2. A "definite" ADR-related CMP was observed in 1.7% of the cases; another 3% of the cases were reported as "possible" ADR-CMP since the role played by the drug could not be clearly defined. "Definite" ADR-CMP was fatal in eight patients (0.6%) while "possible" ADR-CMP was fatal in 13 patients (1.0%). Among the possible co-factors examined, the following ones were found to be significantly associated with the occurrence of a "definite" ADR-CMP: (a) total dose of ADR; (b) vincristine when given both before and concomitantly with ADR; (c) bleomycin when given before ADR; and (d) radiotherapy to the mediastinum when given concomitantly with ADR. Furthermore, none of 182 patients receiving ADR by slow infusion developed a "definite" ADR-CMP, while 2% of the patients treated by bolus injection did so. The occurrence of a "possible" ADR-CMP was found to be significantly associated with two pre-existing pathologic conditions (electrocardiogram [ECG] abnormalities and hypertension) but not with the treatment-related co-factors for the "definite" ADR-CMP mentioned above. Other variables examined, such as sex, age, cancer type, baseline liver function, and cyclophosphamide treatment, did not seem to influence the risk of ADR-CMP. Data on ECG changes occurring during ADR treatment were also reported and their incidence was found to be strictly related to the frequency of the ECG monitoring.
Collapse
|
144
|
Tubiana M, Henry-Amar M, Hayat M, Breur K, van der Werf-Messing B, Burgers M. Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. Eur J Cancer 1979; 15:645-57. [PMID: 116855 DOI: 10.1016/0014-2964(79)90138-5] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
145
|
Hayat M, Bayssas M, Brulé G, Cappelaere P, Cattan A, Chauvergne J, Clavel B, Gouveia J, Guerrin J, Pommatau E, Muggia F, Mathé G. [Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial]. LA NOUVELLE PRESSE MEDICALE 1979; 8:1231-4. [PMID: 375187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We have conducted a phase II trial of cisdiammino-dichloro platinum (CDDP) which demonstrates its remarkable activity in testis embryonic carcinoma, in ovary carcinoma and in epidermoid cancers, especially head and neck and uterus cervix carcinoma. Its toxicity in mainly digestive and renal. This compound is now indicated in combinations in the case of the above mentioned tumors.
Collapse
|
146
|
Pagnier J, Amegnizin KP, Labie D, Hayat M. Hematological and hemoglobin synthesis studies in a family with deltabeta-thalassemia trait. Acta Haematol 1979; 61:27-32. [PMID: 105537 DOI: 10.1159/000207622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A Basque Spanish family with heterozygous deltabeta-thalassemia is described. Patients with this anomaly usually present hematological findings observed in classical beta-thalassemia, but clinical conditions and unbalanced chain synthesis are less severe. Our propositus, however, presented clinical and biosynthetic data similar to those described in thalassemia intermedia. A family study was also performed.
Collapse
|
147
|
Mathé G, Hayat M, Misset JL, Bayssas M, Gouveia J, DeVassal F, Delgado M, Gil MA, Ribaud P, Machover D, Slioussartchouk V, Dantchev D. Some new chemotherapeutic agents and combinations possibly available for new adjuvant therapies of minimal disease. Recent Results Cancer Res 1979; 68:439-48. [PMID: 752880 DOI: 10.1007/978-3-642-81332-0_65] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
148
|
Hayat M, Bayssas M, Brule G, Cappelaere P, Cattan A, Chauvergne J, Clavel B, Gouveia J, Guerrin J, Laufer J, Pommatau E, Szpirglas H, Muggia F, Mathe G. Cis-platinum-diammino-dichloro (CPDD) in chemotherapy of cancers. Biochimie 1978. [DOI: 10.1016/s0300-9084(78)80578-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
149
|
Misset JL, Mathé G, Tubiana M, Caillou B, de Vassal F, Pouillart P, Gil M, Tentas C, Hayat M, Schwarzenberg L, Jasmin C, Delgado M, Machover D, Ribaud P, Musset M. Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation. Cancer Chemother Pharmacol 1978; 1:197-202. [PMID: 373920 DOI: 10.1007/bf00257149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall complete remission rate was about 79% for lymphosarcoma and 73% for reticulosarcoma. About 50% of the patients were still in remission in each of the two diseases at 2 years; 60% of lymphosarcoma and 44% of reticulosarcoma patients achieved 2-year survival. This study shows the prognostic value of the WHO classification for lymphosarcoma and reticulosarcoma: the prognosis of prolymphocytic (centrofollicular) lymphosarcoma is far better than that of the lymphoblastic type, which is in turn better than that of the very poor prognosis of the immunoblastic type. The prognosis of reticulosarcoma is intermediate between that of the best-prognosis and that of the poorest-prognosis type of lymphosarcoma.
Collapse
|
150
|
Mathé G, Hayat M, Giralt E, Szpirglas H, Bayssas M, Gouveia J, Ribaud P, Misset J, Machover D. 36 Clinical phase I and II trial of cis platinum (CDDP) and preclinical and clinical phase I studies of malonato platinum (MDP). Biochimie 1978. [DOI: 10.1016/s0300-9084(78)80626-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|